ABSTRACT Mycoplasma synoviae (MS) is an important pathogen of domestic poultry and is prevalent in commercial layers. Avian influenza (AI; H9N2) infections are emerging respiratory problems causing huge economic losses to the poultry industry, especially in the presence of other co-infecting pathogens. The possible role of MS vaccination and response to AI (H9N2) virus in commercial layers was evaluated during this study. Experimental commercial layers were divided into different groups which were identified as follows: non-vaccinated non-challenged (NVNC), non-vaccinated challenged (NVC), vaccinated nonchallenged (VNC), and vaccinated challenged (VC). The titer of AI antibodies was measured pre-and post-challenge to confirm experimental infection. Infected layers showed clinical signs of differing severity, with the most prominent disease signs and mortality (25%) appearing in layers of the VC group. Moreover, the layers in VC group showed a significant decrease in weight and enhanced gross lesions. All infected layers showed positive results for virus shedding; however, the pattern of virus shedding was different, with layers of VC group showing more pronounced virus excretion than the layers in the NVC group. In addition, layers of VC group showed significantly reduced antibody responses and interferon gene expression when compared with the layers of NVC group. The present study revealed that MS vaccine could facilitate replication of avian influenza viruses and thus avian influenza virus infections can be worse after MS vaccination, especially in AIV-endemic areas.
INTRODUCTION
The upper respiratory tract is the target tissue for a variety of different viruses, bacteria, and fungi. Mycoplasmas and avian influenza virus (AIV) are 2 primary pathogens that may co-infect the avian respiratory tract, leading to severe respiratory disease (Stipkovits et al., 2012a; Roussan et al., 2015; Sid et al., 2016 ) and significant economic losses in chicken and turkey production (Alexander, 2007) . Mycoplasma synoviae (MS) is an important pathogen of domestic poultry, causing economic losses to the poultry industry (Kleven, 2008; Umar et al., 2017) . Infection most frequently occurs as a subclinical upper respiratory infection, which can progress to respiratory disease with air sac lesions when exacerbated by other respiratory pathogens (e.g., Newcastle disease virus, infectious bronchitis virus) or when more virulent MS strains are involved (Lockaby et al., 1999) . The infection can also become systemic and result in acute to chronic infectious synovitis (Kleven, 2008) , however, in many cases the infection is asymptomatic. Previous work has revealed that MS infection is rather common in commercial layers (Kleven, 2008) . Transmission may be transovarian or lateral via respiratory aerosols and direct contact. Infection occurs via the respiratory tract and usually affects 100% of the birds in field conditions. Following infection, birds become persistently infected with MS and remain carriers for life (Raviv et al., 2007; Umar et al., 2017) . As a result of the expansion of poultry production and the concentration of large, multiage production complexes within a 3086 restricted geographic area, it is becoming more and more difficult to maintain flocks that are free of MS.
Avian influenza (AI) is becoming a serious threat to poultry of many countries, including Pakistan. AIV (H9N2) is an emerging respiratory pathogen in poultry that has been isolated from different birds from a number of countries and has been reported to have zoonotic potential (Alexander, 2007; Chaudhry et al., 2015; Umar et al., 2015b Umar et al., , 2016a . The initial replication of AIV also takes place in the respiratory epithelium. Lesion development after AIV infection may vary depending on host species, pathogenicity of the infecting virus, and presence of secondary pathogens (Sid et al., 2016; Umar et al., 2016b) . AIV infection is initiated by binding of the virus to specific viral receptors of the host cell. The antiviral immune response mediated by type I interferon (IFN), including IFN-α and IFN-β, was shown to play a protective role during AIV infection in chickens (Meng et al., 2011) . Likewise, IFN-γ (IFN type III) was demonstrated to prevent AIV infections by limiting viral infection at mucosal surfaces in chickens (Reuter et al., 2014; Umar et al., 2017) . AIV (H9N2) have been reported to cause clinical signs of mild severity in immunocompetent layers (Kwon et al., 2006; Stipkovit et al., 2012a,b) while in immunocompromised layers, H9N2 AIV has been shown to result in severe clinical disease, and even mortality (Kwon et al., 2008; Umar et al., 2015a Umar et al., , 2016c . Similarly, co-infection of AIV with other pathogens can lead to increasing severity of clinical signs and mortality rates as well as the virus-shedding period in poultry (Haghighat-Jahromi et al., 2008) . It has been reported that H9N2 AIV circulating in Pakistani poultry has become a novel genotype by exchanging some genes with highly pathogenic H7N3 and H5N1 viruses (Chaudhry et al., 2015) .
MS vaccines are often used to prevent MS infection in breeders; however, little is known about their hostpathogen interaction and effects on AIV replication in poultry models. In vivo studies in chickens showed that Mycoplasma gallisepticum (MG) predisposes birds for subsequent secondary invading pathogens such as H3N8, which may result in more severe clinical signs compared to mono-infected birds with either H3N8 or MG (Stipkovits et al., 2012a) . Pre-infection with MG followed by subsequent H3N8 infection modified the acquired immunity and led to a decrease in MG antibody levels in co-infected groups (Stipkovits et al., 2012b) . Influenza infections in poultry are important because they impact animal health and agricultural trade, and control costs are very high. Since MS vaccines are commonly used in layers and conditions in which the immune system is negatively affected may occur at any time in commercial poultry flocks due to preexisting infections such as MS, we decided to study the replication pattern and immune responses of AI virus on layers previously challenged with MS vaccine. For the purpose of this study, we selected the H9N2 AIV, which has been isolated from live poultry markets in Pakistan. This study addresses the query of whether MS challenge affects virus replication and the host immune response to avian influenza infection.
MATERIALS AND METHODS

Animals: Housing and Management
Eighty Hyline W-36 female pullets were received at the age of 14 wk from a commercial rearing farm, originating from MS-and MG-free parent stock. The birds were monitored for mycoplasma-free status by regular serological examination of the flock during the rearing period. Both rapid slide agglutination tests and blocking enzyme-linked immunosorbent assay (ELISA) for MS and MG gave negative results when sera from layers flock were tested (Feberwee et al., 2005; Stipkovit et al., 2012a) . All birds were declared serologically negative for influenza viruses by hemagglutination inhibition tests prior to experimental infection. The animal study protocol was approved by the Animal Research and Care Committee of the Arid Agriculture University, Rawalpindi, Pakistan, and experimentation was carried out in accordance with institutional and national guidelines. The layers were randomly allocated into 4 equal groups of 20 layers and were housed in 4 separate identical isolation rooms. The layers were placed into isolators with wire flooring at a stocking density of 10 birds per isolator, and each isolation room contained 2 isolators. The isolators were equipped with nipple drinkers. Throughout the experiment birds were provided with 16 h of light per d and feed and drinking water ad libitum. A standard feed without antibacterial agents were provided. Different persons performed the feeding of the layers and the cleaning of the rooms, in order to avoid cross-contamination; however, the management procedures of all groups were identical.
Challenge Organisms
Avian influenza virus, A/layer/Pakistan/10RS3039-284-48/2010 (H9N2) was a reassortant field isolate kindly provided by Dr. Abdul Ghafar from National Agriculture Research Council (NARC), Islamabad, Pakistan. Viral stocks were prepared and titrated in 9-to 10-day-old layer chicken embryonated eggs, and the median embryo infectious dose (EID 50 ) was calculated using previously reported methods (Spackman et al., 2002) . The viral stocks were diluted in medium containing antimicrobials (brain heart infusion [BHI] broth containing 200 U/mL penicillin, 200 μg/mL streptomycin, 100 U/mL polymyxin B sulfate, and 250 μg/mL gentamicin) to yield a final titer of 10 6 EID 50 /mL (Umar et al., 2015a) . MS vaccine used was Vaxsafe R MS (Bioproperties Pty Ltd). The color-changing units (CCU) of the retained vaccine were determined according to the protocol of Meynell & Meynell (1970) using Mycoplasma Experience (ME) broth (Mycoplasma Experience, Reigate, Surrey, UK). Freeze-dried MS vaccine was suspended in 1 mL distilled water and transferred to 50 mL ME broth and incubated at 37
• C until a change of color was observed (within 3 d). For counting the CCU of the MS vaccine, 10-fold dilutions were prepared in ME broth and incubated for 14 d at 37
• C. The final MS concentration was determined as the highest dilution where a color change was observed. It was expressed as CCU/mL according to the Spearman Karber method for quantal data (Hannan, 2000) .
Experimental Design
Layers were individually identified, their individual body weight was measured, and they were divided into groups in such a way that the average body weight of each group did not differ from each other in Student's t-test (Stipkovits et al., 2012a) . Each of the 4 isolation rooms with 20 birds served as an experimental treatment group, and each isolation room contained 2 isolators. The experimental groups were further allocated into 2 subgroups of 10 birds per isolator and each isolator was labeled and monitored separately. The 4 experimental treatments were as follows: non-vaccinated non-challenged (NVNC), non-vaccinated challenged (NVC), vaccinated nonchallenged (VNC) and vaccinated challenged (VC). At 14 wk of age, the NVNC and NVC groups were sham challenged with sterile phosphate-buffered saline (PBS; 1 mL/bird) by intratracheal inoculation while VNC and VC groups were challenged with live MS vaccine by intraocular inoculation. The viability count of the retained vaccine was 6.6 × 10 7 CCU/mL. Therefore, one vaccine dose (∼23 μL) contained 1.5 × 10 6 CCU, which was in accordance with the manufacturer's recommendations (per bird ≥10 5.7 CCU living MS strain MS-H). After 7 d (15 wk of age), groups NVC and VC were challenged separately with LPAI H9N2 virus A/layer/Pakistan/10RS3039-284-48/2010 (10 6 EID50/mL/bird) by intra-tracheal inoculation.
Clinical Examination
The start of the experiment is referred to as d 0 (14 wks of age) and the experimental period lasted for 3 wk (17 wk of age). The birds were observed for clinical signs such as conjunctivitis, nasal discharge, sneezing, tracheal rales, coughing, and difficult breathing for 3 wk then euthanized using pentobarbital sodium (100 mg/kg body weight, IV) for further pathological and microbiological examinations. The body weight of each layer was measured before vaccination against MS (14 wk of age), before challenge with the influenza virus (15 wk of age) and at the end of the study (17 wk of age). Tracheal mucosal thickness was evaluated microscopically by measuring the thickness of the tracheal mucosa. A section of the upper third of the trachea (approximately 2 cm. distal from the larynx) was fixed in 10% neutral buffered formalin, processed for histopathology, cut into 3 μm sections, and stained with hematoxylin and eosin (H&E).The tracheal mucosa thickness was measured at 4 equidistant points on histologic slides of cross sections of tracheas.
Mycoplasma Monitoring
MG and MS antibodies were checked by rapid plate agglutination (RPA) and monoclonal-based blocking ELISAs (MYGA test and MYSY test; Diagnosztikum Kft, Budapest, Hungary). RPA test was performed as described by Feberwee et al., (2005) within 24 h of collection of blood samples. In short, sera diluted 1:2 were tested with the RPA antigen (Nobilis MS/MG antigen; Intervet International, Boxmeer, the Netherlands). If agglutination occurred, the serum was serially diluted from 1:4 to 1:32 in PBS pH 7.2 and re-tested. If a serum agglutinated at a dilution of 1:8 (titer 3 log 2 ) or higher, it was considered to be a specific positive for MS or MG. For ELISA, inhibition of binding of monoclonal antibodies to the antigen by the tested serum (decreased optical density [OD] values) up to 30% was considered negative; inhibition between 30 and 50% indicated suspicious results, and inhibition of more than 50% was considered to be infected as recommended by the manufacturer (Stipkovit et al., 2012a) .
Tracheal swabs from birds and from all the mortality samples were submitted for mycoplasma culture. They were rinsed in normal saline and inoculated in ME agar (Mycoplasma Experience, Reigate, Surrey, UK) and incubated at 37
• C. Mycoplasma isolates were identified by direct immunofluorescence (Feberwee et al., 2005) . Moreover, serum samples were screened for MS antibodies using RPA test (Nobilis MS antigen; Intervet International, Boxmeer, the Netherlands) and blocking ELISA (MYGA test and MYSY test; Diagnosztikum Kft, Budapest, Hungary) at 0, 7, 14, and 21 d post-MS vaccination to monitor mycoplasma infection.
Determination of Virus Shedding
Buccal (B) and cloacal (C) swabs were taken 1 to 8 d post-virus challenge in 1 mL of PBS containing 1% gentamicin to assess virus shedding. RNA was extracted using the QIAamp viral RNA isolation kit (Qiagen, Valencia, CA) according to the instructions of the manufacturer. The virus titer of each sample was determined by using quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR) as described in previous studies (Umar et al., 2015a,b) , qRT-PCR reactions targeting the influenza virus M gene (M52C 5 CTTCTAACCGAGGTCGAAAG 3 and M253R 5 AGGGCATTTTGGACAAAKCGTCTA 3 ) were conducted using QuantiTect R SYBR Green RT-PCR Kit (Qiagen, Hilden, Germany). The quantitative RT-PCR reactions were performed on a Light Cycler R 480, Real-Time PCR system (Roche Diagnostics, Germany) with the following program: the reverse transcriptase step conditions for primer sets were one cycle at 50
• C for 30 min, 95
• C for 15 min followed by 45 cycles at 95
• C for 15 s, 56
• C for 15 s, and 72
• C for 15 s (Spackman et al., 2002) . The virus titer was represented by the mean ± SD of the virus titer per mL of sample (log 10 RNA copies/mL).
Quantification of Cytokine Gene Expression
Blood samples were taken 1 to 8 d post-virus inoculation in EDTA-coated tubes and quantification of IFN-α and IFN-γ gene expression was determined by using QuantiTect TM Probe RT-PCR (Qiagen, Valencia, CA) and different primer sequences for IFN-α and IFN-γ gene in qRT-PCR as reported previously (Loa et al., 2001; Xia et al., 2004) . For endogenous control, 28S rRNA probe was used as described previously (Giulietti et al., 2001; Xia et al., 2004) . The Light Cycler R 480, Real-Time PCR system (Roche Diagnostics, Switzerland) was used for qRT-PCR. The PCR conditions were the same for each targeted gene and are as follows with an initial denaturation at 94
• C for 2 min followed by 45 cycles of denaturation (94
• C for 30 s), annealing (55
• C for 30 s), and extension (72 • C for 1 min). Product specificity was confirmed by melting curves analysis. Each total RNA sample was amplified in triplicate and the mean values were used for further analysis. RNA from individual cell samples was normalized using using the 28S rRNA sequence. For each gene, amplification was verified using 4 10-fold serial dilutions of standard blood cell RNA in the same PCR run.
Expression was determined by comparison to a standard curve. Data are expressed as fold change in cytokine messenger RNA (mRNA) levels in infected groups compared with those from uninfected groups (Guan et al., 2015) .
Serological Examination
Blood samples were taken at d 0 (before virus challenge) 4, 8, and 12 d post-virus challenge for estimation of antibody titer against AIV using same virus batch (8 hemagglutinating units) and 1% chicken red blood cells in hemagglutination inhibition (HI) assays (OIE, 2012) . Antibodies against neuraminidase were not tested. Prior to HI assays, sera were treated with receptor-destroying enzyme (RDE) to remove nonspecific inhibitors in sera as described previously (OIE, 2012) . Serum titers of 1:8 (2 3 ) or lower were considered negative for antibodies against AIV (Umar et al., 2015b) .
Statistical Analysis
The HI titers and the body weights were compared using Student's t-test (Stipkovits et al., 2012a) . A chisquare test for equality of proportions was performed to measure the statistical significance of the mortality. The mean tracheal mucosa thickness was analyzed by the Tukey-Kramer Honestly Significantly Different test (Raviv et al., 2007) . Expression levels of particular cytokines in experimental groups were compared by ANOVA followed by a post hoc Tukey's test (SPSS 13.0 for Windows program; SPSS Inc., Chicago, IL). All HI-negative serum was given a value of 3log 2 . These values represent the lowest detectable level of antibodies in these samples based on the methods used. Statistical significance was set at P < 0.05 unless otherwise stated, and values were expressed as the mean ± standard deviation of the mean (SDM).
RESULTS
Clinical Examination
Layers in the NVNC group remained healthy and active throughout the experiment period and did not show any clinical signs. Similarly, layers in the VNC group did not show any clinical signs except mild anorexia after vaccination. Nevertheless, we have not undertaken tests to screen these layers for any subclinical disease. However, clinical signs of mild to moderate severity including anorexia, sneezing, edema of head, nasal discharge, and gasping were noticed in 16 of 20 birds in the NVC group. On the other hand, clinical signs of severe respiratory disease such as general depression, coughing, respiratory rales, breathing through a partly open beak, mild nasal exudates, and conjunctivitis were more pronounced and seen more frequently (in 20 of 20 layers) in the VC group than in the NVC group (Table 1) . Moreover, signs of respiratory disease were significantly higher (P < 0.05) than in the NVC and VNC groups. Notably, 5 infected layers in the VC group became severely ill due to infection and died at d 4 postinoculation. The prominent symptoms and gross lesions in all the mortality cases were severe dehydration, tracheitis, pneumonia, airsaculitis, and pericarditis (data not shown). Virus challenge (H9N2) was considered the sole cause of death in all the post-challenge mortality cases based on the clinical picture and PCR results.
No statistically significant differences were noted in the average body weights of layer groups measured before MS vaccination, and no difference was observed between the average body weights of VC and NVC groups before LPAI H9N2 virus challenge. At the end of the study, average body weight of the group VC (1,062 ± 17.6) was significantly lower (P < 0.05) than that of the NVNC or VNC (P < 0.05). However, there was non significant difference (P > 0.05) between NVNC (1,289 ± 19.5) and VNC (1,278 ± 13.7) groups. Moreover, the body weight of group VC was significantly lower (P < 0.05) than that of the NVC group (1,175 ± 55.4) ( Table 1) .
Three wk after the MS vaccination, remaining birds were necropsied and examined for gross lesions. Gross lesions on trachea, lungs and airsacs were detected in all birds in the VNC, NVC, and VC groups, with more prominent lesions in the VC group. No bird in the negative control group demonstrated systemic lesions. Statistical analysis of the results indicated that only the lesions in the VC group were statistically significantly different from the negative control. Microscopically, the major lesions in the affected birds (VC) were chronic tracheitis, bronchitis, and chronic lymphocytic airsacculitis with multinucleated giant cells (data not shown). During the necropsy, tracheas were collected for thickness analysis from all birds ( Table 2) . Tracheal thickness results (due to cellular hyperplasia) for all challenged groups (NVC, VC) were statistically greater than the tracheal thickness of the NVNC, having more prominent thickness in VC group (Table 2 ). The differences in tracheal thickness between the VNC and NVNC groups were numerically obvious but not statistically different. The differences in tracheal thickness between the NVC and the VC groups were not statistically different. The microscopic nature of the tracheal lesions in NVC and VC groups was similar and consisted of lymphocytic tracheitis.
Mycoplasma Monitoring
The mycoplasma status of the study's 4 experimental groups was tested by mycoplasma culture, RPA test, and ELISA; the MS test results are summarized in Table 3 . All groups were negative to mycoplasma on the initial screening and at the point of the MS vaccination.
The birds in NVNC and NVC groups remained negative to mycoplasma throughout the experiment. The VNC and VC groups were positive for MS on the 7, 14, and 21 d post-challenge examinations. All the groups remained MG negative throughout the experiment. Compared with birds in group VNC, birds in group VC had MS cultured more frequently from tracheal swabs (P > 0.005). Anti-mycoplasma antibody titers in VNC and VC were significantly higher than NVNC and NVC. In addition, the birds in the VC group showed significantly lower mycoplasma antibody titers than the birds. In addition, in the birds in VC group showed significantly reduced anti-mycoplasma antibody response than birds in VNC (data not shown).
Infection and Viral Shedding
All layers were negative for H9N2 AIV by serology and virus isolation in eggs prior to inoculation. All layers in inoculated groups became infected with H9N2 AIV as determined by detection of the H9N2 AIV matrix gene in B and C swabs. As shown in Figure 1 , layers in the VC group had higher level of virus shedding (P < 0.05), than those in the NVC group post-infection. Moreover, C swabs revealed different pattern of virus shedding, showing less virus shedding in all groups than B swabs post-infection. These results suggest that replication of H9N2 LPAI virus enhanced in layers of VC group. The time to peak H9N2 AIV shedding in swabs varied between groups as determined by real time RT PCR results (Figure 1) . Layers in the group NVC had peaks for AIV shedding in B and C swabs at d 4 post-virus inoculation while VC group had a peak virus shedding at d 3 post-virus inoculation. Moreover, virus shedding period was shorter in layers of NVC group than those in the group VC.
Quantification of Cytokines
To evaluate the effect of MS vaccine and H9N2 virus infection on the cytokine gene expression, IFN-α and IFN-γ mRNA were quantified by real-time RT-PCR. There was an early and significant increase (P < 0.05) in the expression levels of both IFN-α and IFN-γ mRNA in layers of NVC group than layers of the group VC at 1 to 8 d post-virus inoculation (Figures 2 and  3) . Interestingly, layers in the group VC showed higher IFN-γ mRNA expression than IFN-α; however, this difference was non-significant (P > 0.05). Layers in the VNC group showed relatively lower levels of IFN-α and IFN-γ mRNA (P < 0.05) except at 7 and 8 d post-virus challenge, showing an immunotoxic or immunosuppressive behavior of MS. Moreover, IFN-γ and IFN-α had a peak of mRNA expression at 6 and 8 d post-virus challenge. 
Serological Examination
The sera from the layers in the NVNC and the VNC groups were negative in the HI test (data not shown) while the layers in NVC and VC groups were positive for the inoculated virus by HI test at 4, 8, and 12 d postvirus infection (Table 4 ). The HI titer for layers of the NVC group were significantly higher (P < 0.05) than in layers of the VC group. Collectively, the geometric mean titer was lower (P < 0.05) in the layers of the VC group than in the layers in the NVC group at 4, 8, and 12 d post-virus infection. In our study, the geometric mean titers of NVC and VC groups ranged from log 2 5.8 at d 4 post-virus infection to log 2 8.6 at d 12 postvirus infection, and Log 2 4.4 at d 4 post-virus infection to log 2 7.2 at d 12 post-virus infection, respectively.
DISCUSSION
The coinfection of avian mycoplasmas and influenza viruses in poultry has been observed in field conditions. A unique genotype of H9N2 AIV having some genome similarity to H7N3 virus is circulating in poultry farms of Asian countries (Iqbal et al., 2009; Chaudhry et al., 2015) . Natural AIV/bacterial problems are expected to occur at the same time and have been reported in poultry (Pan et al., 2012; Pu et al., 2012) , but the effects of such combinations on the health status of layer is not well known. The objective of this study was to investigate the possible effects of MS vaccine on the replication and immune responses of AIV-infected layers. AI (H9N2) infections have become endemic in poultry of many countries and MS vaccines have been used Table 4 . HI titers for AI of sera collected from virus inoculated chicken in different groups. regularly in breeder flocks to control mycoplasma infections; therefore, it is important to understand the consequences of AI infection in layers previously exposed to MS vaccines. Our data suggest that MS vaccine modifies the outcomes of H9N2 infections by changing pattern of replication and immune responses. The presented data demonstrate that H9N2 AIV caused obvious clinical signs, induced significant reduction of body weights, antibody titer, cytokine expression and increased virus shedding in buccal and cloacal swabs in layers previously vaccinated against MS. Infection with H9N2 AIV produced mild clinical signs and lesions in the layers of the NVC group. These findings are in line with previous studies that revealed mild infections when H9N2 AIV inoculated experimentally in poultry (Lee et al., 2007; Umar et al., 2015a) . In addition, our findings revealed higher pathogenicity of reassortant H9N2 viruses currently circulating in Pakistan than previous viruses of the same subtype. However, clinical signs and lesions were more pronounced in layers of group VC than VNC and NVC groups. Sid et al. (2016) reported that MG and H9N2 may attach and possibly infect the same cell and lead either synergistically or additively to the destruction of the epithelial layer. Biological properties of M. synoviae including attachment and destruction of epithelial cells could contribute to such effect. It can be speculated here that severe clinical signs linked to H9N2 AIV infections in present study were due to enhanced replication and immunosuppression in the presence of MS vaccines. Delayed viral clearance in MS-vaccinated birds could be another possible reason for enhanced replication and pathogenicity. Moreover, there was a significant decrease (P < 0.05) in body weight of those layers previously vaccinated against MS followed by virus challenge compared to those infected with H9N2 AIV only (NVC) at the end of experiment. Similarly, severe clinical symptoms were observed after co-infection with MG and H3N2 (Stipkovits et al., 2012a,b) . Similar results were reported when chickens were infected with H9N2 in combination with Staphylococcus aureus, Haemophilus paragallinarum, or Ornithobacterium rhinotracheale. More severe clinical signs were observed in co-infected birds compared to mono-infected ones (Kishida et al., 2004; Pan et al., 2012) . Moreover, AIV promoted bacterial growth compared to mono-infected group. Co-infection studies in mice with influenza virus and Streptococcus pneumoniae showed that the viral infection may promote bacterial colonization (Nakamura et al., 2011) .
The severity of the tracheal lesions that were induced by the MS vaccine strain brings into question the prevailing assumption of MS as a benign infection in layers. Indeed, the affected layers appeared clinically normal, but it is likely that birds with such altered tracheas will be more susceptible to disease agents and environmental contaminants. The tracheal damage caused by MS challenge is likely short in duration, so the time in which birds have altered tracheas is also likely of short duration.
We assume that the injured trachea would allow the AIV to attain a greater level of receptor binding and penetration that would result in enhanced replication. Our experiment suggests that the AIV could induce significant high mortality in birds previously vaccinated against MS. This suggests that the intratracheal AI challenge by itself was not enough to produce severe disease and mortality in layers, and that the MS challenge or another co-infectious agent was required to induce the mortality.
It is well known that mycoplasmas can cause excessive release of pro-inflammatory cytokines, inhibit phagocytosis, and affect the functions of B and T lymphocytes, which may lead to immunosuppression (Stipkovits et al., 2012b) . Therefore, the presence of MS vaccine may predispose the host to several other viral and bacterial infections. It was also demonstrated in immunosuppressed layers that the H9N2 AIV induced a high viral load in organs (Kwon et al., 2008; Umar et al., 2015a) . It is well known that immunosuppression can increase disease susceptibility to various bacteria and viruses in poultry (Subler et al., 2006) . Host cellmediated immune response is considered important in the pathogenesis of avian influenza viruses and plays an important role in recovery from viral infection (Wells et al., 1981) . Moreover, H9N2 AIV infection in layers previously vaccinated against MS is characterized by high viral load in oropharyngeal and cloacal secretions, suggesting that MS can enhance viral replication. MS challenge may also be limiting host clearance of the viral infection leading to increased viral loads. It may not have anything to do with enhancing viral replication.
To further elucidate the role of the MS vaccine on innate immune response during H9N2 infections, we investigated IFN type I and type III mRNA expression. It was reported that IFN-α and IFN-γ play an important role in the protection of avian species against viral infections including influenza virus, infectious bronchitis virus, and Newcastle disease virus (Marcus et al., 1999; Meng et al., 2011; Reuter et al., 2014) . Our study indicates that MS vaccine resulted in down regulation of IFN-α and IFN-γ gene expression. This down regulation may facilitate H9N2 infection by suppression of the antiviral immune response in layers compared to H9N2 mono-infected layers. On the other hand, we may speculate that IFN-α and IFN-γ expression levels may directly correlate with virus replication rates. Diminished cell-mediated, humoral immune responses, and IFN gene expression hamper viral clearance, leading to high viral load in layers. Collectively, the geometric mean titer was significantly higher (P < 0.05) and developed faster in the birds of NVC group than VC, suggesting that MS vaccine may modulate immune responses and consequently lead to disturbances in the pathogenesis of AIV. Poor seroconversion and decreased cytokine expression can lead to poor diagnosis and enhance replication of avian influenza viruses.
The present study demonstrates that MS vaccines can modify AIV replication and immune responses, and their combination could result in severe clinical sign and disease, which in commercial production can lead to high economic losses due to poor weight gain, decreased egg production, and mortality. The present study revealed MS vaccine enhanced pathogenesis of AI infection significantly and indicates that MS vaccines can act as a complicating factor during avian influenza infections in layers. Further studies are warranted to elucidate the mechanism of immunomodulation, which may subsequently lead to the improvement of vaccination strategies and other new strategies to control respiratory pathogens in domestic and wild poultry.
